Pharmaceutical company Binnopharm Group estimates its business at more than ₽100 bln, the company's CEO Rustem Muratov told RBC Investments in an interview discussing a potential IPO. Binnopharm Group is interested in Chinese stock exchanges as an IPO platform, but in order to enter one of them it is necessary to first build a local business, which is what company is currently doing.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept